Aleor Dermaceuticals receives final USFDA approval for cold sore drug
Alembic
Pharmaceuticals Limited
(Alembic) announced that its
wholly-owned subsidiary, Aleor
Dermaceuticals Limited (Aleor)
has received final approval from
the US Food & Drug
Administration (USFDA) for its
Abbreviated New Drug
Application (ANDA) for
Docosanol Cream, 10 per cent (OTC).
The approved ANDA is therapeutically equivalent to the reference listed drug
product (RLD) Abreva Cream, 10 per cent (OTC) by GlaxoSmithKline Consumer
Healthcare. Docosanol Cream, 10 per cent (OTC), is used for cold sores or fever
blisters on the face or lips.
Alembic has received a cumulative total of 166 ANDA approvals (142 final
approvals and 24 tentative approvals) from the USFDA
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!